Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping up the FDA funding pace

Executive Summary

The House approves a continuing resolution Sept. 24 that funds most of the federal government, including FDA, at fiscal 2008 appropriation levels through March 6, 2009. The money available to FDA will be calculated on the basis of both the level in its appropriations bill and the $150 million added in a supplemental funding package. "Congress is following through with its commitment to provide additional resources for the FDA," notes Rep. Rosa DeLauro, D-Conn., Chair of the House Appropriations panel that oversees the FDA budget. At press time, the Senate was scheduled to vote on the measure on Sept. 27. Without the continuing resolution, funding for the government would cease with the start of fiscal 2009 on Oct. 1. As March approaches, it is likely Congress will pass another continuing resolution to fund the government through the end of fiscal 2009, an appropriations staffer notes. By that time, congressional appropriators will be directing their attention to the FY 2010 spending bills

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel